A
41
4
IP
59
2
VIX
55
-2
KSS
23
2
VRSK
73
3
URI
45
2
PHM
54
2
SHW
55
-9
THC
64
3
WMT
62
2
AON
69
-6
CFG
70
6
LEN
13
2
GWW
60
2
AMP
57
3
MNST
54
-2
MSI
60
2
FRT
55
7
NOC
45
-2
PWR
63
4
A
41
4
IP
59
2
VIX
55
-2
KSS
23
2
VRSK
73
3
URI
45
2
PHM
54
2
SHW
55
-9
THC
64
3
WMT
62
2
AON
69
-6
CFG
70
6
LEN
13
2
GWW
60
2
AMP
57
3
MNST
54
-2
MSI
60
2
FRT
55
7
NOC
45
-2
PWR
63
4
Financhill
Back

Ultragenyx Pharmaceutical Stock Predictions

Meet the founder that's revolutionizing smartphones

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
11

RARE
Ultragenyx Pharmaceutical

Last Price:
$35.13
Seasonality Move:
14.41%

7 Day Trial

ALL ACCESS PASS

$ 7

Apple's Drop in iPhone Sales Opens the Door for New Entrant

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Ultragenyx Pharmaceutical Stock Forecast

  • Over the next 52 weeks, Ultragenyx Pharmaceutical has on average historically risen by 7.3% based on the past 11 years of stock performance.
  • Ultragenyx Pharmaceutical has risen higher in 6 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 54.55%
  • Is Ultragenyx Pharmaceutical Stock Undervalued?
    The current Ultragenyx Pharmaceutical [RARE] share price is $35.37. The Score for RARE is 11, which is 78% below its historic median score of 50, and infers higher risk than normal.
  • RARE is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.

Will Ultragenyx Pharmaceutical Stock Go Up Next Year?

  • Over the next 52 weeks, Ultragenyx Pharmaceutical has on average historically risen by 7.3% based on the past 11 years of stock performance.

Ultragenyx Pharmaceutical Stock Rating

Sell
11
Ultragenyx Pharmaceutical (RARE) is a Sell

Is Ultragenyx Pharmaceutical overpriced?

  • Ultragenyx Pharmaceutical has risen higher in 6 of those 11 years over the subsequent 52-week period, corresponding to a historical accuracy of 54.55%

Ultragenyx Pharmaceutical Stock Price History

Is RARE stock going to rise?

  • Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and RARE is experiencing buying pressure, which is a positive indicator for future bullish movement.

Stock Information

Stock Info

Exchange:
NASDAQ
Country:
United States
Industry:
Biotechnology
Sector:
Health Care
Type:
stock
Website:
ultragenyx.com

52-Week Data

52-Week High:
60.37
52-Week Low:
33.53

Prediction Charts

Market Cap:
3.3B
Price in USD:
35.37
Volume:
570.9K
Beta:
1.12

Technical Analysis

SMA50:
41.31
SMA100:
43.57
SMA200:
46.95
52-Wk Change:
-24.08%

Stock Predictions

  • Is Ultragenyx Pharmaceutical stock public?
    Yes, Ultragenyx Pharmaceutical is a publicly traded company.
  • What is the Ultragenyx Pharmaceutical stock quote today?
    The Ultragenyx Pharmaceutical stock price is 35.37 USD today.
  • How to buy Ultragenyx Pharmaceutical stock online?
    You can buy Ultragenyx Pharmaceutical shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.

14-Day Historical Data

Date Opening Closing Minimum Maximum
Mar-14 39.32 39.34 40.06 39.05
Mar-17 39.11 39.64 40.07 38.48
Mar-18 39.02 38.86 39.52 38.65
Mar-19 38.86 39.68 40.15 38.70
Mar-20 39.33 38.89 40.21 38.86
Mar-21 38.53 39.18 39.28 38.18
Mar-24 39.44 39.36 39.87 38.99
Mar-25 39.19 38.69 39.19 38.12
Mar-26 38.77 37.98 38.77 36.71
Mar-27 38.44 38.89 39.21 37.98
Mar-28 38.64 37.82 38.76 37.70
Mar-31 36.91 36.21 36.98 35.53
Apr-1 36.06 33.84 36.25 33.69
Apr-2 33.53 35.37 35.42 33.53

Ultragenyx Pharmaceutical Earnings

Ultragenyx Pharmaceutical Earnings Report: Per Share Ultragenyx Pharmaceutical Earnings Q1 Q2 Q3 and Q4 last year and next year.

Ultragenyx Pharmaceutical Forecast Revenue Growth

Ultragenyx Pharmaceutical Stock Analysis: Historical quarterly revenues per share for Ultragenyx Pharmaceutical and historical quarterly revenue growth:

  • Analysts estimate an earnings increase this quarter of $0.17 per share, a decrease next quarter of $0.05 per share, an increase this year of $0.81 per share, and an increase next year of $1.90 per share.

* Ultragenyx Pharmaceutical stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.